IP Library › Granted Patent US 7,402,303
Granted Patent B2
US 7,402,303 · App. 10/398,457 · Granted Jul 22, 2008

Chemokine mutants in the treatment of multiple sclerosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,402,303
App. No.
10/398,457
Granted
Jul 22, 2008
Kind
B2
Abstract

Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.

Claims (2)

1. A mutated human RANTES, consisting of the amino acid sequence of SEQ ID NO:2.

2. A pharmaceutical composition for the treatment of multiple sclerosis, comprising as an active ingredient the mutant human RANTES of claim 1 together with a pharmaceutically acceptable excipient.

Assignments (3)
CHANGE OF NAME Recorded Nov 25, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023569/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019966/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2004
From: PROUDFOOT, AMANDA; WELLS, TIMOTHY N.C.; KOSCO-VILBOIS, MARIE
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 014927/0834 →